Interim report of the safety and immunogenicity endpoints from the Phase II/III study has been submitted to the Drug Controller General of India (DCGI) f...
Lack of access to qualified health personnel combined with an alarming prevalence of noncommunicable diseases (NCDs) such as cardiometabolic diseases (CMDs...
On 23 January 2023, the acceptance period during which DSM Shareholders can tender their DSM Ordinary Shares into the Exchange Offer was extended as not al...
TheracosBio recently received FDA approval for Brenzavvy™ (bexagliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor Piramal suppor...
Sanofi (India) announced that it has received marketing authorization for its diabetes drug Soliqua™ (in pre-...
© 2025 Biopharma Boardroom. All Rights Reserved.
